No, I’m not talking about CYDY. I’m talking about either a big Pharma company having their own orphan status drug they are developing or for example, purchasing a small company that has a drug with orphan status and when they buy that company and develop it, they get the credit and they can apply it to one of their blockbuster drugs while they continue to develop the orphan drug. So to their bottom line, they get accelerated approval in a six month period as opposed to 10 months, therefore giving them four more months of revenue if they do get an approval.